According to Pituitary and Endocrine Society recommendations, cabergoline (CAB) therapy can be discontinued after 2 years in hyperprolactinemic patients who fit certain criteria. Previous studies found recurrence rates ranging between 26 and 69 %. Whether CAB therapy can be successfully discontinued after one unsuccessful withdrawal is unknown.

Second attempt to withdraw cabergoline in prolactinomas: a pilot study / Kwancharoen, Ratchaneewan; Auriemma, RENATA SIMONA; Yenokyan, Gayane; Wand, Gary S; Colao, Annamaria; Salvatori, Roberto. - In: PITUITARY. - ISSN 1386-341X. - 17:5(2014), pp. 451-6-456. [10.1007/s11102-013-0525-x]

Second attempt to withdraw cabergoline in prolactinomas: a pilot study

AURIEMMA, RENATA SIMONA;COLAO, ANNAMARIA;
2014

Abstract

According to Pituitary and Endocrine Society recommendations, cabergoline (CAB) therapy can be discontinued after 2 years in hyperprolactinemic patients who fit certain criteria. Previous studies found recurrence rates ranging between 26 and 69 %. Whether CAB therapy can be successfully discontinued after one unsuccessful withdrawal is unknown.
2014
Second attempt to withdraw cabergoline in prolactinomas: a pilot study / Kwancharoen, Ratchaneewan; Auriemma, RENATA SIMONA; Yenokyan, Gayane; Wand, Gary S; Colao, Annamaria; Salvatori, Roberto. - In: PITUITARY. - ISSN 1386-341X. - 17:5(2014), pp. 451-6-456. [10.1007/s11102-013-0525-x]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/617937
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact